COMy 2019 | Second interim analysis of the EMN02 trial

Michele Cavo

Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses the second interim analysis of the EMN02 trial (NCT01208766), which is the largest academic trial so far that aims to compare upfront transplant vs. standard dosing and consolidation vs. no consolidation for multiple myeloma. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.

Share this video  
Similar topics
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
EMN02
COMy 2019
Interview
17th May 2019
More from Michele Cavo
What is induction therapy for autologous stem cell transplanation?
Myeloma 2016: Panel discussion on the status of genomics
Conflicting results of the EMN02 and staMINA trials
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals